Search results
Results from the WOW.Com Content Network
What I like about the stock is its combination of growth and value. Amgen trades at 17 times its consensus 2024 EPS estimate, a bargain next to Eli Lilly at a forward price-to-earnings ratio of 60 ...
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
Therefore, Amgen's combination of above-average yield, a strong growth profile, and a compelling valuation make its stock worth considering ahead of the Fed's anticipated rate cuts in 2025.
A more liquid stock may lower the bid-ask spread on the stock, making it less costly for investors to transact in the stock. To regain compliance with a stock exchange’s rules.
Amgen (AMGN) closed the most recent trading day at $194.94, moving -0.23% from the previous trading session.
For premium support please call: 800-290-4726 more ways to reach us
Amgen (AMGN) beats Q2 estimates for both earnings and sales. It maintains its previously-issued sales guidance while raising the earnings range. Stock dips.
Amgen (AMGN) closed at $224.46 in the latest trading session, marking a -1.43% move from the prior day.